首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SDF1 |
| Uniprot No | P48061 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-89aa |
| 氨基酸序列 | KPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVC IDPKLKWIQEYLEKALNK |
| 预测分子量 | 8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SDF1(CXCL12)重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *"SDF-1α/CXCR4 signaling promotes migration of transplanted bone marrow mesenchymal stem cells towards the pancreas in rats with acute pancreatitis"*
**作者**: Li X et al.
**摘要**: 研究证明，SDF1α重组蛋白通过CXCR4受体介导的信号通路，促进骨髓间充质干细胞向急性胰腺炎损伤部位的迁移，为干细胞治疗提供机制依据。
---
2. **文献名称**: *"Recombinant SDF-1α protein induces angiogenesis in vitro and in vivo"*
**作者**: Salcedo R et al.
**摘要**: 发现重组SDF1α蛋白可通过激活内皮细胞CXCR4受体，显著促进体外血管形成和小鼠体内缺血模型的血管新生，提示其潜在治疗缺血性疾病的价值。
---
3. **文献名称**: *"Engineering recombinant SDF-1 variants with enhanced stability and function for myocardial repair"*
**作者**: Segers VFM et al.
**摘要**: 通过蛋白质工程改造SDF1重组蛋白，提高其半衰期和生物活性，证明改良后的蛋白能更有效募集干细胞至心肌梗死区域，促进组织修复。
---
以上文献均聚焦于SDF1重组蛋白在疾病治疗(如组织损伤修复、血管再生)中的作用机制或改良策略。如需具体发表年份或期刊信息，可进一步补充检索。
**Background of SDF1 Recombinant Protein**
Stromal cell-derived factor 1 (SDF1), also known as C-X-C motif chemokine ligand 12 (CXCL12), is a small signaling protein belonging to the chemokine family. It plays a critical role in regulating cell migration, proliferation, and survival by interacting with its primary receptor, CXCR4. and a secondary receptor, CXCR7. SDF1 is widely expressed in various tissues, including bone marrow, liver, and lymph nodes, and is essential for embryonic development, immune cell trafficking, and stem cell homing.
The recombinant SDF1 protein is produced using genetic engineering techniques, typically in prokaryotic (e.g., *E. coli*) or eukaryotic expression systems (e.g., mammalian cells). This allows for large-scale production of highly pure, bioactive SDF1 with consistent quality, overcoming limitations of natural extraction methods. Recombinant SDF1 retains the native protein’s structure and function, enabling precise experimental and therapeutic applications.
In research, SDF1 recombinant protein is widely used to study its role in cancer metastasis (due to its involvement in tumor microenvironment signaling), tissue regeneration (by recruiting stem/progenitor cells to injury sites), and inflammatory diseases. Clinically, it holds therapeutic potential for conditions like myocardial infarction, neural damage, and hematopoietic disorders. However, its dual role in promoting both tissue repair and pathological processes (e.g., cancer progression) necessitates careful modulation in therapeutic contexts.
Ongoing studies focus on engineering SDF1 variants or delivery systems to enhance stability, receptor specificity, and targeted action, aiming to optimize its therapeutic efficacy while minimizing off-target effects.
×
